Raymond James & Associates’s Intellia Therapeutics NTLA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q3 | $3.66M | Sell |
178,254
-29,041
| -14% | -$597K | ﹤0.01% | 1863 |
|
|
2024
Q2 | $4.64M | Buy |
207,295
+52,671
| +34% | +$1.18M | ﹤0.01% | 1630 |
|
|
2024
Q1 | $4.25M | Buy |
154,624
+20,253
| +15% | +$557K | ﹤0.01% | 1697 |
|
|
2023
Q4 | $4.1M | Buy |
134,371
+29,997
| +29% | +$915K | ﹤0.01% | 1661 |
|
|
2023
Q3 | $3.3M | Buy |
104,374
+34,458
| +49% | +$1.09M | ﹤0.01% | 1711 |
|
|
2023
Q2 | $2.85M | Buy |
69,916
+16,998
| +32% | +$693K | ﹤0.01% | 1837 |
|
|
2023
Q1 | $1.97M | Buy |
52,918
+31,818
| +151% | +$1.19M | ﹤0.01% | 2039 |
|
|
2022
Q4 | $736K | Buy |
21,100
+2,769
| +15% | +$96.6K | ﹤0.01% | 2612 |
|
|
2022
Q3 | $1.03M | Buy |
18,331
+4,717
| +35% | +$264K | ﹤0.01% | 2368 |
|
|
2022
Q2 | $705K | Sell |
13,614
-486
| -3% | -$25.2K | ﹤0.01% | 2671 |
|
|
2022
Q1 | $1.03M | Sell |
14,100
-3,134
| -18% | -$228K | ﹤0.01% | 2564 |
|
|
2021
Q4 | $2.04M | Sell |
17,234
-10,952
| -39% | -$1.3M | ﹤0.01% | 2158 |
|
|
2021
Q3 | $3.78M | Buy |
28,186
+3,592
| +15% | +$482K | ﹤0.01% | 1687 |
|
|
2021
Q2 | $3.98M | Sell |
24,594
-1,633
| -6% | -$264K | ﹤0.01% | 1636 |
|
|
2021
Q1 | $2.11M | Buy |
26,227
+7,880
| +43% | +$632K | ﹤0.01% | 1971 |
|
|
2020
Q4 | $998K | Buy |
18,347
+5,217
| +40% | +$284K | ﹤0.01% | 2341 |
|
|
2020
Q3 | $261K | Sell |
13,130
-4,354
| -25% | -$86.5K | ﹤0.01% | 3020 |
|
|
2020
Q2 | $368K | Sell |
17,484
-1,130
| -6% | -$23.8K | ﹤0.01% | 2789 |
|
|
2020
Q1 | $228K | Buy |
18,614
+350
| +2% | +$4.29K | ﹤0.01% | 2936 |
|
|
2019
Q4 | $268K | Buy |
+18,264
| New | +$268K | ﹤0.01% | 3132 |
|
|
2018
Q3 | – | Sell |
-8,688
| Closed | -$238K | – | 3539 |
|
|
2018
Q2 | $238K | Sell |
8,688
-3,839
| -31% | -$105K | ﹤0.01% | 3143 |
|
|
2018
Q1 | $264K | Buy |
+12,527
| New | +$264K | ﹤0.01% | 2954 |
|